Earnings summaries and quarterly performance for Alkermes.
Executive leadership at Alkermes.
Richard F. Pops
Detailed
Chief Executive Officer
CEO
BC
Blair C. Jackson
Detailed
Executive Vice President, Chief Operating Officer and Chief Risk Officer
CT
C. Todd Nichols
Detailed
Senior Vice President, Chief Commercial Officer
CC
Craig C. Hopkinson
Detailed
Executive Vice President, Research and Development and Chief Medical Officer
DJ
David J. Gaffin
Detailed
Executive Vice President, Chief Legal Officer and Chief Compliance Officer
JR
Joshua Reed
Detailed
Senior Vice President, Chief Financial Officer
Board of directors at Alkermes.
Research analysts who have asked questions during Alkermes earnings calls.
DT
Douglas Tsao
H.C. Wainwright & Co.
6 questions for ALKS
Also covers: APLS, ARGX, ARQT +21 more
Joseph Thome
TD Cowen
6 questions for ALKS
Also covers: AMLX, ARDX, ARWR +12 more
MG
Marc Goodman
Leerink Partners
6 questions for ALKS
Also covers: ACAD, ALDX, AMLX +14 more
UR
Umer Raffat
Evercore ISI
6 questions for ALKS
Also covers: AMGN, BHC, BIIB +15 more
Jason Gerberry
Bank of America Merrill Lynch
5 questions for ALKS
Also covers: AMPH, ARWR, AXSM +23 more
Leonid Timashev
RBC Capital Markets
5 questions for ALKS
Also covers: ADCT, AXSM, CMPS +11 more
Ami Fadia
Needham & Company, LLC
4 questions for ALKS
Also covers: ACAD, AVDL, AXSM +12 more
AV
Ashwani Verma
UBS Group AG
4 questions for ALKS
Also covers: ACAD, ALVO, AXSM +14 more
David Amsellem
Piper Sandler Companies
4 questions for ALKS
Also covers: ABBV, AMGN, AMPH +27 more
Paul Matteis
Stifel
4 questions for ALKS
Also covers: ABOS, ACAD, ALNY +11 more
UE
Uy Ear
Mizuho Securities
4 questions for ALKS
Also covers: ARQT, EOLS, NBIX +6 more
Ben Burnett
Stifel
3 questions for ALKS
Also covers: ALLO, FATE, IDYA +2 more
CD
Charles Duncan
Cantor Fitzgerald & Co.
3 questions for ALKS
Also covers: ACAD, ATAI, AXSM +12 more
DH
David Huang
Deutsche Bank
3 questions for ALKS
Also covers: APD, HRMY, LIN +1 more
JF
Jessica Fye
JPMorgan Chase & Co.
3 questions for ALKS
Also covers: ALNY, AMRN, ASND +23 more
JB
Joel Beatty
Baird
3 questions for ALKS
Also covers: ACAD, AMLX, ARGX +11 more
Akash Tewari
Jefferies
2 questions for ALKS
Also covers: APLS, ARGX, ARVN +15 more
AJ
Anya John
Jefferies
2 questions for ALKS
DH
David Hoang
Citigroup
2 questions for ALKS
Also covers: ACAD, AVDL, AXSM +8 more
JL
Joon Lee
Truist Securities
2 questions for ALKS
Also covers: ADVM, AXSM, CNM +15 more
JP
Julian Pino
Jefferies
2 questions for ALKS
Also covers: ACAD, ALEC, ALNY +3 more
LH
Luke Herrmann
Baird
2 questions for ALKS
Also covers: CPRX, CRNX, PTCT
RL
Rudy Li
Chardan Capital Markets
2 questions for ALKS
Also covers: ACAD, MNMD, PRAX +3 more
YC
Yiyi Chen
Mizuho Securities
2 questions for ALKS
Adam Ferrari
J.P. Morgan
1 question for ALKS
Also covers: BMRN, HALO, IMCR
A
Alice
Bank of America
1 question for ALKS
Also covers: MLYS
AA
Alice Avanian
Piper Sandler
1 question for ALKS
Anastasia Parafestas
Jefferies
1 question for ALKS
Also covers: EXEL
AN
Andrea Newkirk
Goldman Sachs
1 question for ALKS
Also covers: ABCL, ARWR, DAWN +9 more
Chi Eze
Bank of America
1 question for ALKS
CS
Chris Shibutani
Goldman Sachs Group, Inc.
1 question for ALKS
Also covers: ABBV, BMY, BNTX +11 more
DA
David Amsalem
Piper Sandler
1 question for ALKS
H
Hoyanon
UBS
1 question for ALKS
Karishma Raghuram
Goldman Sachs
1 question for ALKS
Also covers: EXEL, LNTH, RVNC
Katherine Wang
Jefferies
1 question for ALKS
Also covers: APLS, IRWD
LK
Lou Kerman
Baird
1 question for ALKS
MR
Manoj Radder
Jefferies
1 question for ALKS
Also covers: ARVN
MG
Mark Goodwin
Leerink Partners
1 question for ALKS
OR
Omar Rafat
Evercore ISI
1 question for ALKS
PM
Paul Matisse
Stifel Financial Corp.
1 question for ALKS
Also covers: ABOS
TL
Troy Langford
TD Cowen
1 question for ALKS
Also covers: AXSM, JAZZ, NTLA
Yuri
Mizuho
1 question for ALKS
Recent press releases and 8-K filings for ALKS.
Alkermes Outlines Sleep Medicine Market Strategy and Pipeline Progress
ALKS
M&A
New Projects/Investments
Product Launch
- Alkermes is establishing itself as a major player in the sleep medicine market through its orexin franchise, alixorexton, and the acquisition of Avadel, which added LUMRYZ to its portfolio.
- The company has initiated a Phase III program for alixorexton for narcolepsy, comprising three 12-week studies in NT1 and NT2, testing both once-daily and split dosing, following its Breakthrough designation.
- Alkermes is expanding its orexin pipeline with ALKS 7290 for ADHD and ALKS 4510 for fatigue, with initial proof-of-concept data for ALKS 7290 anticipated in the second half of 2026.
- The company's base business is strong and cash-generative, with proprietary products expected to contribute approximately $1.4 billion to the projected $1.6-$1.7 billion top line this year, and LUMRYZ generated over $280 million last year.
- Data for LUMRYZ in idiopathic hypersomnia (IH) is expected in Q2 2026.
4 days ago
Alkermes Discusses Strategic Shift to Sleep Medicine and Orexin Pipeline Expansion
ALKS
New Projects/Investments
M&A
Guidance Update
- Alkermes has completed a significant transition, becoming a major player in the sleep medicine market through the acquisition of Avadel and the development of alixorexton, positioning the company strongly for 2026.
- The company unveiled its Phase 3 program for alixorexton, comprising two studies in NT-1 and one in NT-2, with primary endpoints including the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS), and will test both QD and split dosing.
- Alkermes is expanding its orexin pipeline, with ALKS 7290 for ADHD expected to show initial proof-of-concept data in the second half of 2026, and is also exploring applications for fatigue.
- The base business, including LYBALVI, is described as vibrant, strong, and cash-generative, having transformed into a proprietary products business generating approximately $1.4 billion of the projected $1.6 billion or $1.7 billion total for the current year, enabling aggressive pipeline investment.
4 days ago
Alkermes Details Sleep Medicine Strategy and Orexin Pipeline Progress at TD Cowen Conference
ALKS
M&A
New Projects/Investments
- Alkermes has transitioned into a major player in the sleep medicine market through the acquisition of Avadel and the development of its orexin franchise, including alixorexton.
- The company's base business is strong and cash generative, with proprietary products expected to contribute $1.4 billion of the projected $1.6-$1.7 billion revenue this year, enabling aggressive investment in its expanding pipeline.
- The Phase 3 program for alixorexton, an orexin 2 receptor agonist, will consist of three studies (two in NT-1 and one in NT-2), with 12-week durations and primary endpoints including the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS). The drug received Breakthrough designation at the end of last year.
- Alkermes is expanding its orexin pipeline into new indications, with initial proof-of-concept data for ALKS 7290 in ADHD expected in the second half of 2026.
4 days ago
Alkermes plc Announces CEO Succession Plan
ALKS
CEO Change
Management Change
Executive Compensation
- Richard F. Pops will retire as Chief Executive Officer of Alkermes plc on July 31, 2026, after 35 years in the role. He will continue to serve as non-executive Chairman and Senior Advisor until December 31, 2026.
- Blair C. Jackson, the current Executive Vice President, Chief Operating Officer, has been appointed as the new Chief Executive Officer, effective August 1, 2026.
- In connection with his retirement, Mr. Pops will receive a monthly cash retainer of $75,000 while serving as a Senior Advisor and an annual retainer of $40,000 for his service as non-executive Chairman.
Feb 25, 2026, 2:31 PM
Alkermes Reports Q4 2025 Results and Provides 2026 Outlook
ALKS
Earnings
M&A
CEO Change
- Alkermes reported nearly $1.5 billion in total revenues for 2025, with proprietary product sales growing 9% year-over-year to approximately $1.2 billion, and adjusted EBITDA of $394 million.
- For 2026, the company expects total revenues between $1.73 billion and $1.84 billion and adjusted EBITDA in the range of $370 million to $410 million, reflecting the acquisition of Avadel.
- The acquisition of Avadel closed in February 2026, adding LUMRYZ, which generated approximately $279 million in net sales in 2025 and is projected to contribute an additional $315 million to $335 million in net sales to Alkermes for the remainder of 2026.
- Alkermes plans to initiate Phase III for alixorexton in narcolepsy this quarter, following FDA Breakthrough Therapy designation, and will advance other orexin candidates (ALKS 7290 and ALKS 4510) into Phase II studies in the second half of 2026.
- Richard Pops will transition the CEO role to Blair Jackson this summer, remaining as chairman.
Feb 25, 2026, 1:00 PM
Alkermes Reports Q4 2025 Results, Issues 2026 Guidance, and Details Strategic Initiatives
ALKS
Earnings
Guidance Update
M&A
- Alkermes reported total revenues of nearly $1.5 billion for the year ended December 31, 2025, with proprietary product sales growing 9% year-over-year to approximately $1.2 billion, and achieved $394 million in adjusted EBITDA.
- For 2026, the company anticipates total revenues to be in the range of $1.73 billion-$1.84 billion and adjusted EBITDA between $370 million-$410 million.
- The acquisition of Avadel closed in February 2026, integrating LUMRYZ, which generated approximately $279 million in net sales in 2025 and is expected to contribute $350 million-$370 million in total revenue for 2026.
- Alkermes plans to initiate Phase 3 for alixorexton in narcolepsy in Q1 2026, following its FDA Breakthrough Therapy designation, and expects data from the LUMRYZ Phase 3 study in idiopathic hypersomnia in Q2 2026.
Feb 25, 2026, 1:00 PM
Alkermes Announces Q4 2025 Results and 2026 Financial Expectations
ALKS
Earnings
Guidance Update
M&A
- Alkermes reported FY 2025 total revenue of $1,475.9 million, GAAP Net Income of $241.7 million, and diluted GAAP EPS of $1.43.
- For Q4 2025, the company generated total revenue of $384.5 million, with VIVITROL net sales of $124.1 million, ARISTADA net sales of $97.2 million, and LYBALVI net sales of $94.1 million.
- The company provided FY 2026 financial expectations, projecting total revenues between $1,730 million and $1,840 million and an Adjusted EBITDA between $370 million and $410 million, alongside a GAAP Net Loss ranging from ($115) million to ($135) million.
- The acquisition of Avadel Pharmaceuticals plc closed on February 12, 2026, and is expected to augment revenue growth and profitability, with LUMRYZ net sales projected between $315 million and $335 million for the period of February 12, 2026, to December 31, 2026.
- FY 2025 and FY 2024 results reflect the expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August 2024.
Feb 25, 2026, 1:00 PM
Alkermes Reports Strong 2025 Results, Provides 2026 Guidance, and Announces Strategic Developments
ALKS
Earnings
Guidance Update
M&A
- Alkermes reported nearly $1.5 billion in total revenues and $394 million in adjusted EBITDA for 2025, primarily driven by $1.2 billion in proprietary product net sales.
- For 2026, the company expects total revenues between $1.73 billion and $1.84 billion and adjusted EBITDA between $370 million and $410 million.
- The recently completed acquisition of Avadel, which closed in February 2026, adds LUMRYZ, a narcolepsy treatment that generated approximately $279 million in net sales in 2025. Alkermes expects LUMRYZ to contribute an additional $315 million-$335 million in net sales for the remainder of 2026.
- Alkermes plans to initiate Phase 3 for its orexin candidate, alixorexton, in narcolepsy this quarter, following FDA Breakthrough Therapy designation. The company anticipates a GAAP net loss of $115 million-$135 million in 2026 due to acquisition-related accounting.
- Richard Pops will transition from CEO to Chairman this summer, with Blair Jackson becoming the new CEO.
Feb 25, 2026, 1:00 PM
Alkermes plc Reports Q4 and Full-Year 2025 Financial Results and Provides 2026 Expectations
ALKS
Earnings
Guidance Update
M&A
- Alkermes plc reported total revenues of $1.48 billion and GAAP net income of $242 million for the year ended December 31, 2025, with diluted GAAP earnings per share of $1.43. Proprietary product net sales increased approximately 9% year-over-year to $1,184.6 million in 2025.
- For 2026, the company expects total revenues of $1,730 million to $1,840 million and a GAAP net loss of ($115) million to ($135) million.
- Key strategic developments include the recent completion of the Avadel acquisition on February 12, 2026, which is expected to contribute LUMRYZ net sales of $315 million to $335 million (for the period of Feb 12 - Dec 31, 2026). Additionally, the Alixorexton Phase 3 clinical program in narcolepsy is expected to initiate in Q1 2026.
Feb 25, 2026, 12:05 PM
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc
ALKS
M&A
Debt Issuance
New Projects/Investments
- Alkermes plc completed the acquisition of Avadel Pharmaceuticals plc on February 12, 2026, integrating Avadel's FDA-approved product, LUMRYZ®, into its commercial portfolio and accelerating its entry into the sleep medicine market.
- The acquisition, expected to be accretive in 2026, was financed with approximately $750 million of cash from Alkermes' balance sheet and $1.525 billion in term loans due in 2031.
- For 2026, Alkermes anticipates $40 million in Q1 transaction-related costs, $180 million for LUMRYZ inventory fair value step-up, $95 to $105 million in intangible asset amortization, and $75 to $85 million in net interest expense.
Feb 12, 2026, 12:37 PM
Quarterly earnings call transcripts for Alkermes.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more